1 **Baculovirus-vectored precision delivery of large DNA cargoes in human genomes**

2

3 Francesco Aulicino[1*], Martin Pelosse[1#], Christine Toelzer[1], Julien Capin[1], Parisa Meysami[1],

4 Mark Simon Dillingham[1], Christiane Schaffitzel[1] and Imre Berger[1,2]*

5

6 [1] BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry,

7 1 Tankard's Close, University of Bristol, Bristol BS8 1TD, United Kingdom

8 [2] Max Planck Bristol Centre for Minimal Biology, School of Chemistry, University of Bristol,

9 Clantock's Close, Bristol BS8 1TS, United Kingdom

10

11

12

13 [#] Current address: Laboratoire Chimie et Biologie des Métaux CEA Grenoble, 17 Avenue des

14 Martyrs 38054 Grenoble CEDEX 09 France

15

16 [*] Correspondence to francesco.aulicino@bristol.ac.uk and imre.berger@bristol.ac.uk

17

18   **Abstract:**

19   Precise gene editing and genome engineering by CRISPR technology requires simultaneous

20   delivery of multiple DNA-encoded components into living cells rapidly exceeding the cargo

21   capacity of currently utilized viral vector systems. Here we exploit the unmatched heterologous

22   DNA cargo capacity of baculovirus to resolve this bottleneck. We implement hybrid DNA

23   techniques (MultiMate) for rapid and error-free assembly of currently up to 25 functional DNA

24   modules in a single baculoviral vector enabling CRISPR-based genome engineering. Utilizing

25   homology-independent targeted integration (HITI), we achieve up to 30% correct genome

26   interventions in human cells, including precision docking of large DNA payloads in the *ACTB*

27   locus. We demonstrate baculovirus-vectored delivery of prime-editing toolkits for seamless

28   DNA search-and-replace interventions achieving, with a single vector, highly efficient

29   cleavage-free trinucleotide insertion in the *HEK3* locus without any detectable indels. Our

30   approach thus unlocks a wide range of editing and engineering applications in human cell

31   genomes.

32

33 **Main**

34 CRISPR/Cas represents a game-changing gene editing tool[1]. A programmable DNA nuclease

35 (Cas9) is precisely guided to a specific DNA locus by means of a short single guide RNA

36 (sgRNA) to elicit double strand DNA breaks (DSBs) subsequently repaired through non-

37 homologous end-joining (NHEJ) introducing small insertions-deletions (indels), giving rise to

38 frameshift mutations and functional gene knock-outs (KOs)[1]. Unpredictable indels that

39 likewise occur are however undesirable in the context of therapeutic gene editing. Precise gene

40 editing in contrast is typically achieved through homology directed repair (HDR) by providing

41 a DNA template flanked by homology arms of variable length[1,2], resulting in precise gene

42 correction or knock-in (KIs)[1]. HDR activity however is intrinsically low and mostly restricted

43 to S/G2 cell cycle phases[3-5], reducing the efficiency of the desired gene editing outcome.

44 Significant effort is being made to increase the efficacy of CRISPR-HDR by means of small-

45 molecule NHEJ inhibitors[6], cell cycle stabilised Cas9 variants[7,8] and other strategies[9,10],

46 however, gene editing efficiency *in vivo* has remained low.

47 More recently, homology-independent targeted integration (HITI), was shown to

48 efficiently induce base pair precise KIs in both dividing and non-dividing cells[11-13] by

49 exploiting NHEJ and Cas9 cleaved donors, with exciting potential for gene editing applications

50 *in vivo*[11,14]. Moreover, single base substitutions can also be achieved by using base editors

51 (BEs) involving catalytically impaired Cas9 variants fused to cytosine or adenine deaminase

52 [15,16]and, more recently, prime editors (PEs) using Cas9 nickase fused to reverse transcriptase,

53 achieving genomic interventions with little to no indels and reducing the risks associated with

54 DSBs[17]. BE, PE and HITI share in common a reliance on multiple functional DNA and protein

55 elements that must be simultaneously delivered into target cells. This limits their applicability,

56 in particular for future *bona fide* therapeutic interventions that necessitate a systemic approach

57 and where co-transfection of plasmids and proteins, and likewise co-infection of viral vectors,

58   will be problematic or unfeasible. In summary, the large DNA cargo capacity required for

59   implementing these next-generation genomic interventions *in vivo* stands at odds with the

60   limited cargo capacity of available technology, including the currently dominating adeno-

61   associated virus (AAVs) and lentivirus (LVs) vector systems[18]. In marked contrast, baculoviral

62   vectors (BVs) have a heterologous DNA cargo capacity far exceeding AAV and LV[18-20]. BVs,

63   suitably pseudotyped to alter host cell tropism, are already widely used to transduce

64   mammalian cells and living organisms[19-22]. We demonstrated in a proof of concept that BV is

65   suitable for CRISPR-HDR mediated small (~0.7 kb) DNA insertions with low efficacy

66   (~5%)[19,23], as would be expected for HDR[3-5].

67   Here we unlock baculovirus as a vector of choice for next-generation genome

68   intervention approaches, fully exploiting its unprecedented DNA cargo capacity and versatility.

69   We implement and deploy state-of-the-art DNA assembly technology (MultiMate) for error-

70   free bottom-up assembly of multifunctional DNA circuitry comprising the DNA cargo to be

71   inserted as well as all the DNA encoding all CRISPR modalities required to achieve highly

72   efficient genome intervention in a baculovirus-vectored approach.

73

74   **Results**

75   We had previously developed methods to rapidly assemble functional DNA elements into

76   multicomponent circuitry in baculoviral vectors[24-26]. Here, we optimized and fine-tuned our

77   approach by incorporating time-tested MultiSite Gateway recombination modalities to

78   assemble with ease currently up to 25 distinct DNA elements of various sizes (**Fig.1a,**

79   **Extended Data Fig.1a-e, Supplementary Methods**), importantly aiming to significantly

80   reduce prokaryotic elements carried over into the baculovirus which can compromise vector

81   integrity during manufacturing[27] (**Extended Data Fig.1f**). We validated the MultiMate system

82   by expressing the eight subunits of human chaperonin CCT/TRiC complex[28] in insect cells

83   from a BV comprising MultiMate assembled DNA (23 kb) (**Extended Data Fig.1g-j**). We

84   then assessed MultiMate to efficiently deliver large multicomponent DNAs for expression and

85   live cells imaging of up to 7 fluorescently labelled proteins (MultiMate-Rainbow) in human

86   cells (**Fig.1b, Extended Data Fig.2a**). MultiMate assembly yielded remarkably low error rates

87   validating our approach (**Extended Data Fig.2b**). We deployed BVs harbouring 18 and 23.4

88   kb of MultiMate assembled functional DNA to efficiently transduce HEK293T, HeLa, H4 and

89   SH-SY5Y leading to homogeneous expression and correct subcellular localization of all

90   fluorescently labelled proteins (**Fig.1b, Extended Data Fig.2c**). Moreover, we created

91   MultiMate-CellCycle (9.1 kb) as an improved cell cycle tracking tool implementing FUCCI

92   reporters[29] as well as H2B-iRFP expression for accurate transduction efficiency monitoring

93   and cell cycle stage assessment (**Fig.2c, Extended Data Fig.2d,e**). MultiMate-CellCycle BVs

94   efficiently transduced HEK293T, HeLa, H4 and SH-SY5Y cells highlighting differences in

95   their respective cell cycle progressions (**Extended Data Fig.2f**) and enabling 12-hrs time lapse

96   imaging on living HeLa cells, allowing cell cycle tracking also during FUCCI-unstained stages

97   (M-G1 transition) (**Fig1.c, Supplementary Video 1**). These results comprehensively validate

98   the MultiMate assembly platform enabling a wide range of baculovirus-vectored applications.

99

100 **Baculovirus-vectored homology independent targeted integration (HITI)**

101 To date, baculovirus-vectored gene editing approaches were confined to CRISPR-HDR of

102 small insert DNAs with low efficacy[19,22,23]. HITI toolkits using a viral vector required donor

103 and Cas9/sgRNA to be split between two AAVs due to their limited cargo capacity[11], restricting

104 successful gene editing to the fraction of co-infected cells. Moreover, manufacturing complete

105 'all-in-one' HITI vectors is not possible when viral packaging is performed in mammalian cells

106 (typically HEK293T for AAV, LV), because simultaneous expression of Cas9 and sgRNA

107 would inevitably excise the HITI donor, fatally compromising virus production. In marked

108   contrast, BVs are manufactured in insect cells, where the mammalian promoters controlling

109   Cas9 and sgRNA expression are silent and all-in-one HITI construct packaging into the BV is

110   thus entirely feasible.

111   To minimise unpredictable indels and maximise correctly-edited alleles, we sought to

112   analyse and compare HDR and HITI-2c[11] strategies by targeting the intronic β-actin (*ACTB*)

113   locus, introducing a synthetic C-terminal exon fused to mCherry and a self-cleaving peptide

114   (T2A)[30] followed by a puromycin selection cassette (**Fig.2a**). We eliminated any possibility of

115   leaky expression by outfitting our DNAs with the Cas9 inhibitor AcrII4[31] under control of a

116   dual prokaryotic and baculoviral promoter (J23119-polH). An additional module expressing

117   eGFP under the constitutive CMV promoter was added to track transduction efficiency. Despite

118   comparable transduction of HEK293T cells, Multimate-HITI-2c resulted in a 3- to 4-fold

119   higher percentage of mCherry+ cells compared to Multimate-HDR (**Fig.2b-c, Extended Data**

120   **Fig.3h**). The BV backbone was rapidly diluted as we expected, while mCherry+ cells were

121   stably maintained over time (**Fig.2b-c**) with absolute gene editing efficiencies reaching 5%

122   (HDR) and 20% (HITI-2c) (**Fig.2c**). Notably, when compared to plasmid transfection,

123   baculovirus-vectored delivery increased gene editing efficiency up to 4-fold regardless of the

124   approach (**Extended Data Fig.3a-c**). To confirm correct gene editing, BV transduced cells

125   were selected with puromycin and then expanded in the absence of selective pressure,

126   demonstrating stably maintained mCherry expression in close to all (>98%) cells (**Fig.2d**).

127   Successful editing was confirmed by PCR genotyping (**Extended Data Fig.3e**), the expected

128   mCherry subcellular localization (**Fig.2e,Extended Data Fig.3f**) and the predicted

129   ACTB::mCherry molecular weight (68 kDa) in western blot (**Fig.2f, Extended Data Fig.3g**).

130   MultiMate-HITI-2c ACTB outperformed HDR editing in all BV transduced cell lines

131   (**Extended Data Fig.3h**). For optimal efficacy, we prepared VSV-G pseudotyped BVs[19] and

132   transduced HEK293T, HeLa, H4 and SH-SY5Y at different multiplicities of transduction

133   (MOT) achieving higher transduction (up to 100%) and editing efficiencies (up to 30%)

134   depending on the cell line (**Fig.2h, Extended Data Fig.3i**). To our best knowledge this is the

135   first assembly and delivery platform to enable efficient homology independent targeted

136   integration in mammalian cells using a single all-in-one viral vector.

137

138   **Safe-harbour integration of large DNA payloads**

139   Precision docking of large multicomponent DNA circuitry in mammalian genomes is a

140   prerequisite for *bona fide* genome engineering, but remains an impeding challenge for currently

141   available viral delivery systems which are constrained by their intrinsic packaging limitations

142   (AAV: ~4 kb; LV: ~8 kb)[18,20]. We assessed the aptitude of our system for precision DNA

143   docking exploiting MultiMate-HITI-2c (**Supplementary Methods**). We used a new Cre

144   insertion site to generate a series of HITI-2c payloads ranging from 4.7 kb to 18 kb with

145   mTagBFP as a transduction efficiency reporter, resulting in all-in-one MultiMate plasmids of

146   up to 30 kb (**Fig.3a**). Transduction with EMBacY BV[32] markedly outcompeted plasmid

147   transfection and editing in HEK293T (**Extended Data Fig.4a-d**). Upon puromycin selection,

148   cells remained >98% mCherry+ (**Extended Data Fig.4e**) confirming precise 5'-end

149   integration. We observed silencing of the 3'-end fluorescent marker correlated with cargo size,

150   which we could fully restore by hygromycin selection (**Fig.3b, Extended Data Fig.4f**). We

151   confirmed correct integration by PCR genotyping and Sanger sequencing (**Fig.3c,d**). We

152   deployed MultiMate-HITI-2c 18K-CGH (30 kb) for baculovirus-vectored delivery with VSV-

153   G pseudotyped BV achieving 100% transduction efficiency in both HEK293T and SH-SY5Y

154   giving rise to 20% and 30% absolute genomic insertion efficiency, respectively (**Fig.3e**). Of

155   note, mCherry expression remained constant over time in the absence of any selective pressure

156   while silencing of 3' eGFP expression (**Fig.3f,g**) was again promptly restored by

157   puromycin/hygromycin selection, remaining stable thereafter (**Fig.3h**). Our results

158 demonstrate that safe-harbour integration of extensive DNA payloads with base-pair precision

159 can be achieved with high-efficiency using all-in-one MultiMate-HITI-2c BVs, setting the

160 stage for future large synthetic gene regulatory network engineering in human genomes.

161

162 **Highly efficient baculovirus-vectored search-and-replace gene editing**

163 Base editors (BEs)[15,16] and prime editing (PEs)[17] are new additions to the CRISPR toolkit that

164 could potentially correct up to 89% of the human disease-causing mutations in the absence of

165 DNA cleavage[17]. PE in particular, can be harnessed to precisely edit genomes with little to no

166 indels production. PE exploits the nickase Cas9-H840A fused to reverse transcriptase from

167 MMLV (PE2) to make a ssDNA copy of the engineered PegRNA at the edited site, allowing

168 for the generation of all possible point mutations, insertions (up to 44 bp) and deletions (up to

169 80 bp) in the absence of DNA cleavage[17]. We chose here to insert a CTT trinucleotide in the

170 *HEK3* locus using the prime editing enzyme PE2[17]. PE2 coding sequence spans 6.3 kb

171 (excluding promoter) encoding for a 240 kDa protein that previously could be virally delivered

172 only through multiple split-intein lentiviral vectors[17] due to cargo limitation, but is entirely

173 within the packaging size of BV. We therefore assembled MultiMate-PE2 comprising PE2,

174 *HEK3* PegRNA cassette, VSV-G (for pseudotyping), aeBlue chromoprotein[33] (for visual

175 readout of virus titer) and mTagBFP (for transduction tracking) (**Fig4. a**, **Extended Data**

176 **Fig.5a**). MultiMate-PE2 plasmid transfection resulted in 13% CTT insertion in *HEK3* as

177 assessed by Sanger sequencing and deconvolution using ICE[34] (**Extended Data Fig.5b,c**).

178 MultiMate-PE2 BVs production could be easily monitored (**Extended Data Fig.5d**) with

179 excellent transduction efficiencies in the cell lines tested (**Fig4b,d and Extended Data Fig.5e).**

180 Sanger sequencing on *HEK3* locus amplicons from unsorted cells showed correct CTT editing

181 with base-pair precision (**Fig.4c**) with correct editing contributions after deconvolution of 15-

182 45%, depending on the cell line, and undetectable indels (**Fig.4e**). We increased the

183   transduction titer and observed a dose-dependent effect boosting correct editing events (up to

184   45%) again without any indels detected (**Extended Data Fig.5f-i**) unlocking PE to our

185   baculovirus-vectored approach for future, conceivably multiplexed applications including

186   therapeutic interventions.

187

188   **Discussion**

189   The limited packaging capacity of currently dominating viral vectors (AAV, LV) markedly

190   constrains precise genome editing interventions[18,20]. We demonstrated here the efficacy of our

191   baculovirus-vectored approach to overcome this limitation. We developed a rapid error-free

192   DNA assembly (MultiMate) to facilitate vector construction with a view to improve BV

193   manufacturing. We implemented homology independent targeted integration (HITI) for precise

194   DNA insertion achieving efficient C-terminal tagging in the *ACTB* locus, markedly

195   outcompeting HDR efficiency. Using our approach, we demonstrated precision safe-harbour

196   integration with outstanding efficacy of large multicomponent DNA payloads. There is no

197   indication that we reached the cargo limit of baculovirus-vectored delivery. In fact, given the

198   wide variation in size of naturally occurring baculoviruses[35] we expect that delivery of DNA

199   cargos exceeding 100kb will likely be feasible, enabling insertion of entire metabolic pathways

200   and gene regulatory networks in safe-harbour sites or elsewhere in genomes, additionally

201   incorporating DNA insulator elements[36,37] to support sustained gene expression. Importantly,

202   we demonstrate the utility of our approach for seamless search-and-replace gene editing by

203   implementing recently developed prime editing (PE) technology[17]. Particularly PE, is

204   considered safer when compared to HDR or HITI-2c, which both rely on DNA cleavage. Using

205   a single baculovirus vector, we achieved PE-mediated trinucleotide insertion (CTT) in the

206   *HEK3* locus with up to 45% efficiency in the absence of detectable indels. Taken together, our

207   results establish baculovirus as a vector of choice for precision engineering of large DNA

208 cargoes in human genomes, and we anticipate baculovirus-vectored large-scale genome

209 interventions, even combining safe-harbour integration with concomitant, if needed

210 multiplexed, base or prime editing strategies, enabling complex synthetic biology and

211 therapeutic approaches in the future.

212

213 **References**

214 1   Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nature*
215   *Protocols* **8**, 2281 (2013).
216 2   Shy, B. R., MacDougall, M. S., Clarke, R. & Merrill, B. J. Co-incident insertion enables
217   high efficiency genome engineering in mouse embryonic stem cells. *Nucleic Acids*
218   *Research* **44**, 7997-8010 (2016).
219 3   Lieber, M. R. The Mechanism of Double-Strand DNA Break Repair by the
220   Nonhomologous DNA End-Joining Pathway. *Annual Review of Biochemistry* **79**, 181-
221   211 (2010).
222 4   Saha, J., Wang, S.-Y. & Davis, A. J. Examining DNA Double-Strand Break Repair in
223   a Cell Cycle-Dependent Manner. *Methods Enzymol* **591**, 97-118 (2017).
224 5   Orthwein, A. *et al.* A mechanism for the suppression of homologous recombination in
225   G1 cells. *Nature* **528**, 422-426 (2015).
226 6   Hu, Z. *et al.* Ligase IV inhibitor SCR7 enhances gene editing directed by CRISPR–
227   Cas9 and ssODN in human cancer cells. *Cell & Bioscience* **8**, 12 (2018).
228 7   Gutschner, T., Haemmerle, M., Genovese, G., Draetta, Giulio F. & Chin, L. Post-
229   translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. *Cell*
230   *Reports* **14**, 1555-1566 (2016).
231 8   Yang, D. *et al.* Enrichment of G2/M cell cycle phase in human pluripotent stem cells
232   enhances HDR-mediated gene repair with customizable endonucleases. *Scientific*
233   *Reports* **6**, 21264 (2016).
234 9   Canny, M. D. *et al.* Inhibition of 53BP1 favors homology-dependent DNA repair and
235   increases CRISPR–Cas9 genome-editing efficiency. *Nature Biotechnology* **36**, 95-102
236   (2018).
237 10   Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR–Cas9
238   genome editing induces a p53-mediated DNA damage response. *Nature Medicine* **24**,
239   927-930 (2018).
240 11   Suzuki, K. *et al.* In vivo genome editing via CRISPR/Cas9 mediated homology-
241   independent targeted integration. *Nature* **540**, 144 (2016).
242 12   Kelly, J. J. *et al.* A Safe Harbor-Targeted CRISPR/Cas9 Homology Independent
243   Targeted Integration (HITI) System for Multi-Modality Reporter Gene-Based Cell
244   Tracking. *bioRxiv*, 2020.2002.2010.942672 (2020).
245 13   Artegiani, B. *et al.* Fast and efficient generation of knock-in human organoids using
246   homology-independent CRISPR–Cas9 precision genome editing. *Nature Cell Biology*
247   **22**, 321-331 (2020).
248 14   Suzuki, K. & Izpisua Belmonte, J. C. In vivo genome editing via the HITI method as a
249   tool for gene therapy. *J Hum Genet* **63**, 157-164 (2018).

250 15 Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable
251   editing of a target base in genomic DNA without double-stranded DNA cleavage.
252   *Nature* **533**, 420-424 (2016).
253 16 Gaudelli, N. M. *et al.* Programmable base editing of A•T to G•C in genomic DNA
254   without DNA cleavage. *Nature* **551**, 464-471 (2017).
255 17 Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks
256   or donor DNA. *Nature* **576**, 149-157 (2019).
257 18 Sung, L.-Y. *et al.* Efficient gene delivery into cell lines and stem cells using
258   baculovirus. *Nature Protocols* **9**, 1882-1899 (2014).
259 19 Mansouri, M. *et al.* Highly efficient baculovirus-mediated multigene delivery in
260   primary cells. *Nature Communications* **7**, 11529 (2016).
261 20 Kalesnykas, G. *et al.* Comparative Study of Adeno-associated Virus, Adenovirus, Bacu
262   lovirus and Lentivirus Vectors for Gene Therapy of the Eyes. *Curr Gene Ther* **17**, 235-
263   247 (2017).
264 21 Kost, T. A., Condreay, J. P. & Jarvis, D. L. Baculovirus as versatile vectors for protein
265   expression in insect and mammalian cells. *Nat Biotechnol* **23**, 567-575 (2005).
266 22 Hindriksen, S. *et al.* Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome
267   editing in human cells. *PLoS One* **12**, e0179514 (2017).
268 23 Mansouri, M., Ehsaei, Z., Taylor, V. & Berger, P. Baculovirus-based genome editing
269   in primary cells. *Plasmid* **90**, 5-9 (2017).
270 24 Bieniossek, C. *et al.* Automated unrestricted multigene recombineering for multiprotein
271   complex production. *Nat Methods* **6**, 447-450 (2009).
272 25 Sari, D. *et al.* The MultiBac Baculovirus/Insect Cell Expression Vector System for
273   Producing Complex Protein Biologics. *Adv Exp Med Biol* **896**, 199-215 (2016).
274 26 Nie, Y. *et al.* ACEMBL Tool-Kits for High-Throughput Multigene Delivery and
275   Expression in Prokaryotic and Eukaryotic Hosts. *Adv Exp Med Biol* **896**, 27-42 (2016).
276 27 Pijlman, G. P., de Vrij, J., van den End, F. J., Vlak, J. M. & Martens, D. E. Evaluation
277   of baculovirus expression vectors with enhanced stability in continuous cascaded
278   insect-cell bioreactors. *Biotechnol Bioeng* **87**, 743-753 (2004).
279 28 Yam, A. Y. *et al.* Defining the TRiC/CCT interactome links chaperonin function to
280   stabilization of newly made proteins with complex topologies. *Nat Struct Mol Biol* **15**,
281   1255-1262 (2008).
282 29 Bajar, B. T. *et al.* Fluorescent indicators for simultaneous reporting of all four cell cycle
283   phases. *Nature methods* **13**, 993-996 (2016).
284 30 Liu, Z. *et al.* Systematic comparison of 2A peptides for cloning multi-genes in a
285   polycistronic vector. *Scientific Reports* **7**, 2193 (2017).
286 31 Rauch, B. J. *et al.* Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* **168**,
287   150-158.e110 (2017).
288 32 Fitzgerald, D. J. *et al.* Protein complex expression by using multigene baculoviral
289   vectors. *Nat Methods* **3**, 1021-1032 (2006).
290 33 Liljeruhm, J. *et al.* Engineering a palette of eukaryotic chromoproteins for bacterial
291   synthetic biology. *Journal of Biological Engineering* **12**, 8 (2018).
292 34 Hsiau, T. *et al.* Inference of CRISPR Edits from Sanger Trace Data. *bioRxiv*, 251082
293   (2018).
294 35 Vijayachandran, L. S. *et al.* Gene gymnastics: Synthetic biology for baculovirus
295   expression vector system engineering. *Bioengineered* **4**, 279-287 (2013).
296 36 Alhaji, S. Y., Ngai, S. C. & Abdullah, S. Silencing of transgene expression in
297   mammalian cells by DNA methylation and histone modifications in gene therapy
298   perspective. *Biotechnology and Genetic Engineering Reviews* **35**, 1-25 (2019).

299 37   Harraghy, N., Gaussin, A. & Mermod, N. Sustained transgene expression using MAR
300   elements. *Curr Gene Ther* **8**, 353-366 (2008).
301
302

303   **Figure Legends**

304   **Figure 1. MultiMate enables rapid modular assembly of multifunctional DNA circuitry**

305   **for efficient baculovirus-vectored delivery in human cells. a**, MultiMate assembly platform

306   in a schematic view. Symbols are listed (left panel). attL/R flanked DNA from ENTR plasmid

307   modules (upper box, dashed) are assembled on MultiBac-DEST (lower box) and further

308   combined by *in vitro* Cre-mediated recombination to generate multicomponent MultiMate

309   plasmids, maximally eliminating prokaryotic backbone DNA sequences. MultiMate plasmids

310   are integrated in BVs customized for efficient delivery in human cells (right panel). **b**,

311   Confocal live cell imaging of H4, HeLa, HEK293T and SH-SY5Y 48 hours after transduction

312   with MultiMate-Rainbow BV (upper panel) evidencing in all cells homogeneous sustained

313   expression and correct subcellular localization of H2B-iRFP (nucleus), GTS-mTagBFP

314   (Golgi), mAG-β-catenin (membrane and adherens junctions), EYFP-Tubulin (microtubules),

315   mTFP1-Actin (cytoskeleton), mito-mCherry (mitochondria) and CyOFP1-ER (endoplasmic

316   reticulum). Scalebar, 20 μm. **c**, Twelve-hours confocal time-lapse imaging of live HeLa cells

317   transduced with MultiMate-CellCycle BV (snapshots, **Supplementary Video 1**). Transduced

318   cells constitutively express H2B-iRFP for DNA imaging. mAG-hGeminin and mKO2-hCdt1

319   are stabilised in S/G2 and G1 cell cycle stages, respectively. Upper panel shows G1/S

320   transition, lower panel shows a dividing cell (arrows indicate tracked cells). Scalebar, 10 μm.

321   DNA elements, plasmid topology and cell cycle schematics are illustrated (upper panel).

322

323   **Figure 2. Baculovirus-vectored delivery of complete multicomponent CRISPR/Cas9**

324   **toolkits for homology independent targeted integration (HITI) in human cells. a**, *ACTB*

325   C-terminal tagging strategy: homologous directed repair (HDR) and homology independent

326   targeted integration (HITI-2c) elements within attL1/attR3 sites (triangles) and MultiMate-

327   HITI-2c ACTB all-in-one DNA circuitry comprising Cas9, HITI-2c donor, sgRNA cassette,

328   eGFP reporter. A module encoding AcrII4 Cas9 inhibitor under control of J23119 and polH

329   promoters ensures vector stability. *ACTB* C-terminal exon is replaced with a synthetic exon,

330   tagged with mCherry::T2A::puromycin. **b-c**, HEK293T cells transduced with MultiMate-HDR

331   or MultiMate-HITI-2c BVs in the absence of puromycin selection, at three- and ten-days post-

332   transduction. **b,** Representative FACS plots and **c**, histogram of flow-cytometry data. Mean ±

333   s.d. of n = 3 independent biological replicates. ***P<0.001, Student's t-test. **d-f**, HEK293T

334   transduced with MultiMate HDR or MultiMate HITI-2c BVs after puromycin selection. **d**,

335   Representative flow-cytometry histograms; **e**, Widefield microscopy, Scalebar=20 μm. **f**,

336   Western blot of total protein extracts. Anti-β-actin antibody was used in top panel with anti-

337   TUBULIN as loading control. **g**, Confocal images of HEK293T, HeLa, H4 and SH-SY5Y cells

338   48 hours after transduction with MultiMate-HITI-2c BV. Scalebar is 50 μm. **h**, Histograms of

339   flow-cytometry data of HEK293T, HeLa, H4 and SH-SY5Y 72 hrs after transduction with

340   MultiMate-HITI-2c VSV-G pseudotyped BVs, multiplicity of transduction (MOT) 1 and 10.

341   Transduction efficiency= % of eGFP+ cells; absolute gene editing efficiency = % of Cherry+

342   cells. Mean ± s.d. of n=3 independent biological replicates.

343

344   **Figure 3. Baculovirus-vectored safe-harbour homology-independent integration of large**

345   **DNA cargoes in human genomes. a**, Safe-harbour HITI-2c strategy, HITI-2c payloads within

346   attL1/attR3 sites (triangles) and MultiMate-HITI-2c ACTB all-in-one plasmid carrying Cas9,

347   HITI-2c payload, sgRNA, AcrII4 and mTagBFP reporter. *ACTB* C-terminal exon is replaced

348   with a synthetic exon, tagged with T2A::mCherry::P2A::puromycin (5' integration marker),

349   DNA insert ranging from 4.7 to 18 kb, and distinct 3' integration markers (CMV Hygromycin

350   (CH), CMV eGFP IRES Hygromycin (CGH) or EF1a EYFP-Tubulin IRES Hygromycin

351   (EYH)). **b-c**, HEK293T transduced with the indicated MultiMate-HITI-2c BVs after

352   puromycin and hygromycin selection. **b**, Confocal microscopy. Scalebar, 100 μm. **c**, PCR

353   genotyping. Oligonucleotide pairs (colour coded arrows) for each PCR are shown, their

354   approximative position is depicted in (a). **d**, Sanger sequencing of 5' and 3' genotyping PCRs

355   (indicated by * in (c)) of HEK293T transduced with MultiMate-HITI-2c 18K-CGH BV. **e**,

356   Transduction efficiency (left histogram) and absolute gene editing efficiency (right histogram)

357   of HEK293T and SH-SY5Y 72 hours after transduction with MultiMate-HITI-2c 18K-CGH

358   VSV-G pseudotyped BV, derived from flow-cytometry data. Mean ± s.d. of n = 3 independent

359   biological replicates. **f**, Confocal microscopy pictures of HEK293T and SH-SY5Y 8 days after

360   transduction with MultiMate-HITI-2c 18K-CGH VSV-G pseudotyped BVs in the absence of

361   puromycin or hygromycin selection. **g**, Representative flow-cytometry plots of HEK29T at

362   three- or 24-days post transduction with MultiMate-HITI-2c 18K-CGH VSV-G pseudotyped

363   BV. **h**, Representative flow-cytometry plots of HEK29T transduced with MultiMate-HITI-2c

364   18K-CGH VSV-G pseudotyped BV after puromycin (left) and puromycin/hygromycin

365   selection (right).

366

367   **Figure 4. Highly efficient and indels-free prime-editing by using MultiMate all-in-one BV.**

368   **a**, MultiMate-PE2 for CTT insertion in the HEK3 locus in a schematic view. aeBlue is used

369   for tracking viral amplification and VSV-G for pseudotyping BV, respectively. mTagBFP

370   reports on transfection/transduction efficiency in human cells. **b**, Representative flow-

371   cytometry histograms of HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y cells at 24 hours post

372   transduction with MultiMate-PE2 VSV-G pseudotyped BV. **c**, Representative genotype PCR

373   sanger sequencing of unsorted HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y cells at 96

374   hours post transduction with MultiMate-PE2 VSV-G pseudotyped BV and their respective

375   controls (untransduced parental cell lines). **d**, Transduction efficiencies of HeLa, RPE-1

376   hTERT, HEK293T and SH-SY5Y cells at 24 hours post transduction with MultiMate-PE2

377   VSV-G pseudotyped BV. Mean ± s.d. of n = 3 independent biological replicates. **e**, Percentage

378   of correct editing (CTT insertion) in HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y at 96

379   hours post transduction. Data are derived from sanger sequencing deconvolution (ICE), no

380   indels were detected in any of the conditions. Mean ± s.d. of n = 3 independent biological

381   replicates.

382

383   **Methods**

384   **Gibson assembly of DNA elements**

385   An extensive list of constructs maps and assembly strategies is provided in **Supplementary**

386   **Table 1**. ENTR and DEST vectors were generated using Gibson assembly (NEB Builder Hi-

387   Fi DNA assembly #E2621S) following manufacturer's instructions. Fragments were mixed

388   with a backbone to insert ratio of 1:1 (>3 fragments), 1:2 (<2 fragments), 1:5 (fragments <300

389   bp) in 5 µl total volume and supplemented with 5 ul 2xNEB Builder Hi-Fi mix followed by

390   incubation at 50°C for 1 hour. 2 ul of the assembly mix were transformed into homemade

391   electrocompetent Top10 or Pir+ *E.Coli.* followed by recovery at 37°C while shaking for 1 hour

392   and plating on LB/agar plates with the appropriate antibiotics. All the precursors vectors

393   generated in this study were assembled using Gibson assembly of synthetic DNA fragments,

394   oligonucleotides, digested vectors or PCRs amplified with Herculase II fusion (Agilent#

395   600675). A portion of pENTR-D-TOPO (Invitrogen) was used as backbone for all the pMMK

396   ENTR vectors. attL/R sites on pMMK ENTR vectors were obtained by overlap extent PCRs

397   of long oligonucelotides. attR1-Ccdb-Chlo-attR2 cassettes for generating pMMACE DEST

398   were PCR amplified from pInducer-20[38]. pMMDS DEST was generated by replacing the

399   Chloramphenicol cassette with Ori^{ColE1} PCR amplified from pACEMam1[19]. H2B-iRFP was

400   PCR amplified from pCAG-H2BtdiRFP-IP[39], EYFP-Tubulin and mTFP1-Actin were

401 amplified from 5-colours MultiBac vectors[19]. pMDK 7 kb and 12 kb were generated by cloning

402 promoterless and ATG-less portions of SMG1(NM_015092.5) CDS. Mito-mCherry was

403 generated by fusing mCherry from 7TGC[40] to the COX8 mitochondrial targeting sequence

404 from 5-colours MultiBac vectors[19]. CyOFP1[41] fused to the endoplasmic reticulum targeting

405 sequence (ER) was synthesised by Twist Bioscience. mAG β-catenin was obtained through

406 Gibson assembly of PCR amplified mAG from pL-EF1a mAG-hGeminin[42], and β-catenin from

407 pL-EF1a β-catenin SV40 Puro[43]. Golgi targeting sequence (GTS) mTaBFP was synthesised by

408 Twist Bioscience. polH or p10 cassettes were amplified from MultiBac vectors[32,44], CCT

409 isoforms were PCR amplified from synthetic vectors from GenScript. SpCas9 was PCR

410 amplified from px459[1], sgRNAs cloning was performed by overlap extent PCRs of hU6 and

411 scaffold fragments amplified from px459[1]. HDR and HITI-2c templates were amplified by

412 Gibson assembly of genomic DNA fragments, mCherry was amplified from 7TGC[40], T2A Puro

413 from px459[1]. sgRNAs target in the HITI-2c donors were included as overlapping ends between

414 fragments. polH/J23119 AcrII4[31] was synthesised by Twist Bioscience. In the HITI-2c

415 payloads for safe-harbour integration, mCherry T2A Puro was replaced with T2A mCherry

416 P2A Puro. P2A was generated by overlap extent PCR of long oligonucleotides. The loxP site

417 was PCR amplified from pACEBac1[32,44], Hygromycin, IRES and eGFP were PCR-amplified

418 from p1494 vectors[45]. PE2 was obtained by restriction digestion from pCMV PE2[17] and the

419 HEK3 PegRNA was PCR amplified from pU6-Sp-pegRNA-HEK3_CTT_ins[17]. aeBlue[33] was

420 synthesised by Twist Bioscience and VSVG-G was amplified from pMD2.G (Didier Trono lab,

421 Addgene plasmid # 12259).

422

423 **LR recombination**

424 LR recombination was carried out using LR Clonase II (Thermo Fisher #11791020) or LR

425 Clonase II plus (Thermo Fisher #12538120). Although LR Clonase II plus is specifically

426   designed for MultiSite Gateway recombination, LR Clonase II worked with comparable

427   efficiency in our hands. LR reactions were carried out following manufacturer's instructions.

428   One DEST and four ENTR vectors were diluted to 20 femtomoles/µl each in TE buffer pH 8.0

429   (Thermo Fisher #12090015). 1 ul of each diluted vector was added to a 0.2 ml PCR tube with

430   2 ul LR Clonase II and 3 ul TE buffer, followed by a brief spin and incubation at 25°C for 16

431   hours. The next day the reaction was terminated by addition of 1 ul proteinase K (provided

432   with LR Clonase II enzymes) and incubation at 37°C for 10 minutes. 2-3 ul were transformed

433   into homemade electrocompetent Top10 or Pir[+] *E.Coli*, followed by 2 hours recovery at 37°C

434   and plating on LB/agar plates with the appropriate antibiotics. LR recombination products were

435   predicted using APE[46] with custom recombination reactions. To quickly load MultiMate LR

436   reaction prototype in APE, the following code can be copied and used in Tools/Recombination

437   Reaction Editon/New reaction from clipboard:

438   MultiMate LR Reaction for APE:

```
{ApE recombination reaction:} {MultiMate LR Reaction (1-3-4-5-2)} {{{pMMK ENTR 1} {pMMK
ENTR 2} {pMMK ENTR 3} {pMMK ENTR 4} DEST} {attB1 0 attB3 0 attB4 0 attB5 0 attB2 1}}
```

439

440   When imported as GenBank or Fasta files, the MultiMate LR reaction in APE will

441   automatically recognize pMMK ENTR1-4 vectors and one DEST donors when launched

442   through Tools/Recombination tools. For manual prediction of MultiMate assembly products, a

443   list of the attL/R sequences and their attB products is provided in **Supplementary Table 3**.

444

445   **Cre-mediated recombination of DNA elements**

446   One acceptor and one or multiple donor vectors were assembled using Cre-mediated

447   recombination as previously described[26,32,47]. One acceptor and one or more donors were mixed

448   with a ratio of 1:1.1 in distilled H2O with 0.5 ul (7.5 U) of CRE recombinase (NEB # M0298M)

449   and 1 ul Cre buffer (provided with CRE recombinase) to a final volume of 10 ul in distilled

450 H2O. 500-1000 ng of total DNA were used for each reaction. Cre-reactions were incubated for

451 1 hour at 37°C, followed by heat inactivation at 70°C for 10 minutes. 2-3 ul were transformed

452 into homemade electrocompetent Top10 *E.Coli*, followed by 2 hours recovery at 37°C and

453 plating on LB/agar plates with the appropriate antibiotics. Cre-recombination products were

454 predicted using Cre-ACEMBLER Vers. 2.0 [47].

455

456 **Cell culture methods**

457 Human cells (HEK293T, HeLa, H4, RPE-1 hTERT and SH-SY5Y) were purchased from

458 ATCC and propagated as adherent cultures in 60 or 100 cm dishes in a humidified incubator

459 (37°C, 5% CO2). For passaging cells were washed with phosphate saline buffer (DPBS, Gibco

460 # 14190144), detached using 0.25% Trypsin (Thermo Fisher #25200056) followed by a brief

461 incubation at 37°C, centrifuged at 300x RCF and resuspended in fresh media in a new plate at

462 the desired concentration. Suspension cultures of Sf21 insect cells were grown in 125 ml or

463 250 ml polycarbonate Erlenmeyer flasks with vent cap (CORNING, #431143, #431144) at

464 27°C in a shaking incubator. Sf21 were split every 2/3 days and maintained at concentrations

465 between $0.5\text{-}2\text{x}10^6$ cells/ml. Origin and media formulation recipe for each cell line is reported

466 in **Supplementary Table 4**.

467 For transfection in HEK293T, $2\text{x}10^5$ cells/well were seeded in multi-24 wells. Transfections

468 were carried out using Polyfect (QIAGEN #301105), following manufacturer's instructions.

469 Briefly 500 ng of DNA were resuspended in 25 ul of Optimem (Gibco #31985062),

470 supplemented with 5 ul Polyfect and incubated for 15 minutes at room temperature.

471 Transfection mix was resuspended with 100 ul of complete media and added dropwise to each

472 well. Cells were cultured for at least 48 hours before assessing the phenotype (e.g. fluorescence

473 markers expression).

474

Baculovirus vector amplification

Assembled MultiMate vectors were shuttled on baculovirus genomes (bacmids) propagated in *E.Coli* using Tn7 transposition. 200-1000 ng of MultiMate vector were transformed in chemically competent DH10-MultiBacMam-VSV-G[19], DH10-EMBacY[32] or commercial DH10Bac (ThermoFisher # 10361012) as previously described[32]. Bacteria were streaked on LB/Agar plates with Gentamycin, Kanamycin, Tetracyclin, IPTG and Bluo-Gal and incubated for 24-hours for blue-white screening. White colonies were picked and grown overnight in 3 ml of LB supplemented with Gentamycin/Kanamycin to extract bacmid DNA through alkaline lysis/ethanol precipitation as previously described[32,44].

For transfection in insect cells, 0.8-1x10^6 Sf21 cells/well were seeded on multi-6 well plates in 3 ml of Sf-900 II media. 10 ul of purified bacmid were resuspended in 130 ul Sf-900 II media with 10 ul X-treme XP transfection reagent (Roche # 06366236001) and incubated at room temperature for 15 minutes. The entire transfection mix was added dropwise to a single well and cells were incubated at 27°C in a static incubator. V_0 viral stocks were harvested collecting the supernatant of transfected cells 72-96 hours post transfection as previously described[19,32,47]. 1-3 ml of V_0 viral stocks was added to 10 ml of fresh Sf21 cells at 0.8x10^6 cells/ml. Cells were cultured in 50 ml Falcon tubes while shaking at 27°C and counted every day to monitor cell proliferation and size using Luna cell-counter (LogosBio). Successfully infected cells displayed arrested proliferation and increased average cell size (13-14 μm control, 16-20 μm infected). V_1 viral harvest were collected as previously described 2 days after proliferation arrest (DPA+24)[19,32,47] by centrifugation at 4500 x rcf. 500 μl/1 ml of V_1 viral stocks was added to 50 ml of fresh Sf21 cells at 0.8x10^6 cells/ml in 125 ml Erlenmeyer flasks and cells were cultured at 27°C in a shaking incubator. V_2 viral harvests were collected by centrifugation at 4500 x rcf, and concentrated 20 times by high-speed centrifugation at 11000 x rcf, followed by

499 resuspension in DPBS supplemented with 3% heat inactivated FBS and 1 %Glycerol for

500 storage at -80°C.

501

Baculovirus vector titration and transduction

503 For BV expressing fluorescent markers in human cells, titration was performed as previously

504 described[48]. HEK293T were used to determine viral titers. Briefly $5x10^5$ cells/well were seeded

505 in multi-48 wells plates in 200 ul of complete media. Concentrated virus was serially diluted

506 in DPBS and 50 µl were dispensed to each well.

507 Spinoculation (30' at 600 x rcf at 27°C) was used to enhance transduction as previously

508 reported[48]. 24 hours after transduction, cells were analysed using flow-cytometry to determine

509 the percentage of transduced cells. TU/ml values from dilutions giving less than 20%

510 transduction efficiencies were averaged to estimate the titer as previously described[49] and using

511 **Supplementary Equation 1**. For experiments in which different viral titers were used,

512 multiplicity of transduction (MOT) was calculated as TU/Cn.

513

Confocal and widefield imaging

515 Confocal images were acquired using a Leica Sp8 equipped with 405, 458, 476, 488, 496, 514,

516 561, 594, 633 nm laser lines and 37°C stage. For time lapse confocal experiments on living

517 cells the stage was supplemented with 5% CO2. For higher magnification, cells were plated on

518 Lab-Tek borosilicate multi-8 wells (Thermo Fisher # 155411). For experiments in which

519 transduced cells expressed more than 3 different fluorochromes, laser intensity and detection

520 filters were adjusted to reduce spectral overlap using individual fluorescence controls

521 transfections. Widefield and phase contrast images were acquired using a Leica DMI6000

522 equipped with excitation/emission filters optimised for DAPI, GFP, Rhodamine, Texas Red

523 and Far red.

524

Flow cytometry analysis

526 For flow-cytometry analysis cells were trypsinised and resuspended in complete media

527 supplemented with 3μM DRAQ7 (Abcam #ab109202) to counterstain dead cells. Cells were

528 analysed on a BD Fortessa, fluorochromes were detected as follow: eGFP and EYFP (FITC-

529 A), mCherry (PECF594-A), mTagBFP (BV421-A), DRAQ7 (AlexaFluor700-A). SSC-A and

530 FSC-A were used to discriminate single cells and cell populations by size. FlowJo X was used

531 to analyse FCS files. All data represented are percentages of live single cells (DRAQ7-).

532

PCR genotyping, Sanger sequencing and deconvolution

534 Genomic DNA was extracted with QIAamp DNA Mini Kit (QIAGEN # 51306) following

535 manufacturer's instruction. A list of the predicted gene editing outcome sequences and

536 genotyping oligos is provided in **Supplementary Table 2.** PCRs were performed using

537 KAPA2G Fast Genotyping mix (SigmaAldrich # KK5621) following manufacturer's

538 instruction. Amplicons were run on 0.8% agarose gels, purified using QIAquick Gel Extraction

539 Kit (QIAGEN # 28706) and eluted in distilled ddH2O. For Sanger sequencing 15 ul of purified

540 PCR at 5-10 ng/μl were mixed with 2 μl of diluted (10 μM) sequencing primer and sent to an

541 external sequencing service (Eurofins). Electropherograms (.ab1) from parental and transduced

542 cells were fed into ICE[34] from Synthego for sequence deconvolution and indels/knock-in

543 estimation.

544

Western blot analysis

546 Total protein extracts from HEK293T were obtained by lysing the cells with ice-cold RIPA

547 Buffer (Thermo Fisher # 89901) supplemented with protease inhibitors (Thermo Fisher #

548 78429) for 30' on ice. Insoluble material was pelleted by centrifugation at 16000 x rcf at 4°C

549 for 5 minutes. Total protein extracts from insect cells were obtained as previously described[32].

550 Proteins concentration were determined using Nanodrop. 10 μg protein/sample were stained

551 with Laemmli buffer, boiled at 95°C for 5 minutes, separated using pre-cast NuPage 4-12%

552 Bis-Tris SDS-Gels (Thermo Fisher # NP0321BOX) and transferred to PVDF membranes using

553 iBlot. Membranes were blocked with 5% non-fat dry milk in T-TBS (50 mM Tris-Cl, pH 7.6,

554 150 mM NaCl, 0.5% Tween) for 1 hour at room temperature. Membranes were incubated with

555 primary antibodies diluted 1:1000 in T-TBS 5% milk overnight at 4°C while rocking, followed

556 by 2 T-TBS washes and incubation with HRP-conjugated secondary antibody diluted 1:2000

557 in T-TBS 5% milk for 1 hour at room temperature. Membranes were washed again with T-TBS

558 and developed using Pierce ECL reagents (Thermo Fisher # 34579) following manufacturer's

559 instructions. Finally, membranes were imaged using MyECL Imager.

560 A list of the primary and secondary antibodies used is provided in **Supplementary Table 5**.

561

562 **CCT/TriC complex purification**

563 Recombinant MultiMate-CCT BV was produced as previously described[32] and used to infect

564 Sf21 insect cells at a cell density of 1.0×10^6/mL in Sf-900 II medium. Cells were harvested 72-

565 96 h after proliferation arrest by centrifugation at 1,000 g for 15 minutes. Cell pellets were

566 resuspended in lysis buffer (50 mM HEPES-NaOH, 200 mM KCl, 10 mM Imidazole, 20 %

567 Glycerol, pH 7.5, supplemented with EDTA-free protease inhibitor (Sigma-Aldrich) and

568 Benzonase (Sigma-Aldrich)) and lysed by short sonication. The lysate was cleared by

569 centrifugation at 18,000 rpm, 4°C, in a F21-8x50y rotor (Thermo Fisher Scientific) for 60

570 minutes. The supernatant was loaded on a TALON column (Generon), equilibrated in TALON

571 A buffer (50 mM HEPES-NaOH, 200 mM KCl, 10 mM Imidazole, 20 % Glycerol, pH 7.5)

572 with a peristaltic pump. The column was washed with ten column volumes (CV) of TALON A

573 buffer before eluting the bound protein complex with a step gradient of TALON B buffer (50

574   mM HEPES-NaOH, 200 mM KCl, 250 mM Imidazole, 20 % Glycerol, pH 7.5). The CCT

575   protein complex was buffer exchanged in Heparin A buffer (50 mM HEPES-NaOH, 100 mM

576   KCl, 10 % Glycerol, pH 7.5) while concentrating. It was then subjected to a Heparin column

577   (GE Healthcare) and eluted with a 1M KCl gradient in Heparin A buffer. Fully formed

578   complexes and disassembled subunits were separated on a Superose 6 10/300 column (GE

579   Healthcare) equilibrated in SEC buffer (20 mM HEPES-NaOH, 200 mM KCl, pH 7.5, 1 mM

580   DTT, 10% Glycerol). Peak fractions were pooled and concentrated and the purity of the CCT

581   complex was analyzed by SDS-PAGE.

582

583   **Electron microscopy**

584   For electron microscopy, copper grids with carbon coating (300 mesh, Electron Microscopy

585   Sciences) were glow discharged for 10 s, and 5 µL of purified CCT was placed on the grids for

586   1 min. Afterwards the grid was washed for 15 s and floated onto a drop of filtered 3 % uranyl

587   acetate for 1 min. Excess solution on the grids was blotted off using filter paper between each

588   step. Grids were visualized under a FEI Tecnai 20 transmission electron microscope (TEM),

589   and digital micrographs were taken using a FEI Eagle 4Kx4K CCD camera. Particle picking

590   and processing was performed using RELION 2[50,51], 2D class averages were generated without

591   applying symmetry or reference models.

592

593   **Data availability statement**

594   All plasmid sequences are provided in **Supplementary Table 1**. MultiMate-CellCycle,

595   MultiMate-Rainbow and MultiMate-HITI-2c ACTB reagents will be made available for

596   distribution by Addgene. All other reagents are available from the authors upon reasonable

597   request.

598

Methods References

38   Meerbrey, K. L. *et al.* The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. *Proceedings of the National Academy of Sciences* **108**, 3665 (2011).

39   Miyanari, Y., Ziegler-Birling, C. & Torres-Padilla, M.-E. Live visualization of chromatin dynamics with fluorescent TALEs. *Nature Structural & Molecular Biology* **20**, 1321-1324 (2013).

40   Fuerer, C. & Nusse, R. Lentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway. *PLOS ONE* **5**, e9370 (2010).

41   Chu, J. *et al.* A bright cyan-excitable orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo. *Nature Biotechnology* **34**, 760 (2016).

42   De Jaime-Soguero, A. *et al.* Wnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus. *PLOS Genetics* **13**, e1006682 (2017).

43   Aulicino, F. *et al.* Canonical Wnt pathway controls mESCs self-renewal through inhibition of spontaneous differentiation via β-catenin/TCF/LEF functions. *bioRxiv*, 661777 (2019).

44   Berger, I., Fitzgerald, D. J. & Richmond, T. J. Baculovirus expression system for heterologous multiprotein complexes. *Nat Biotechnol* **22**, 1583-1587 (2004).

45   Aulicino, F., Theka, I., Ombrato, L., Lluis, F. & Cosma, M. P. Temporal perturbation of the Wnt signaling pathway in the control of cell reprogramming is modulated by TCF1. *Stem Cell Reports* **2**, 707-720 (2014).

46   Davis, M. W. ApE - A plasmid editor https://jorgensen.biology.utah.edu/wayned/ape/.

47   Becke, C., Haffke, M. & Berger, I. Cre-ACEMBLER Software User Manual. (2012).

48   Cheng, T. *et al.* [Improving baculovirus transduction of mammalian cells by spinoculation]. *Sheng Wu Gong Cheng Xue Bao* **23**, 546-551 (2007).

49   Lo, W.-H., Chen, C.-Y., Yeh, C.-N., Lin, C.-Y. & Hu, Y.-C. Rapid baculovirus titration based on regulatable green fluorescent protein expression in mammalian cells. *Enzyme and Microbial Technology* **48**, 13-18 (2011).

50   Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. *Elife* **5** (2016).

51   Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. *Journal of Structural Biology* **180**, 519-530 (2012).

Acknowledgement

641   Bristol Centre for Minimal Biology. I.B. is Investigator of the European Research Council

642   (ERC Advanced Grant DNA-DOCK, Project Nr. 834631).

643

644   **Author contributions**

645   I.B. and F.A. conceived and designed the study with input from C.S. and M.S.D.. F.A.

646   performed experiments and analysed results. F.A. and M.P. designed, implemented and

647   validated DNA assembly protocols. C.T. performed protein purification and EM. J.C and P.M.

648   produced and provided reagents. M.S.D., C.S. and I.B. supervised and guided the research.

649   F.A. and I.B. wrote the manuscript with input from all authors.

650

651   **Competing interest statement**

652   I.B. declares shareholding in Geneva Biotech Sàrl and is inventor on patents and patent

653   applications covering DNA methods and baculovirus reagents licensed to Geneva Biotech Sàrl.

654

655   **Additional Information**

656   Supplementary Information contains: Supplementary Methods detailing MultiMate DNA

657   assembly and MultiMate-HITI-2c safe harbour assembly; Supplementary Tables providing

658   sequences, gene editing outcomes and genotyping oligonucleotides sequences, cell lines and

659   antibodies; Supplementary Equation and Supplementary Video.

660

661   **Extended Data Figure Legends**

662   **Extended Data Figure 1. MultiMate assembly protocol and validation. a**, DNA elements

663   are pasted into four distinct ENTR plasmid modules in between attL/R recombination sites

664   (coloured triangles). **b**, One DEST module and four ENTR modules are assembled by LR

665   recombination *in vitro*. DEST plasmids are adapted from MultiBac Acceptor/Donor suite[25,32].

666   In pMMACE DEST, the homing cassette is attR1-Ccdb-Chlo^R-attR2, in pMMDS DEST attR1-

667   Ccdb-Ori^{ColE1}-attR2. **c**, After LR reaction, pMMACE DEST and pMMDS DEST are fused by

668   Cre-recombination. **d**, MultiBac donor plasmids and pMMD DEST vectors can be iteratively

669   added by Cre recombination, barcoded by resistance makers[26]. **e**, MultiMate plasmid is shuttled

670   into the MultiBac BV by Tn7-mediated recombination in *E. Coli*. MultiMate and MultiBac

671   BVs can be further functionalised by *in vitro* Cre-mediated recombination (d-e). **f**, Plasmid

672   size, number of modules and cargo to prokaryotic backbone DNA ratio (green and grey bars,

673   respectively) for hypothetical 1.5 kb expression cassettes. **g**, Assembly strategy for MultiMate

674   plasmid encoding chaperonin CCTs. CCT subunits were pasted into pMMK ENTR plasmid

675   modules comprising baculoviral promoters (polH, p10), assembled by LR reaction into

676   pMMACE DEST and pMMDS DEST, fused by Cre and loaded on EMBacY[32] BV. Expression

677   of MultiMate-CCTs with EMBacY in Sf21 insect cells produces complete CCT/TriC

678   chaperonin. **h**, Western blot of infected Sf21 cells, uninfected cells as control (ctr) with CCT

679   subunit specific antibodies. Anti-His was used to detect His-CCTα. **i**, SDS-PAGE analysis of

680   purified CCT/TriC chaperonin complex. **j**, Negative-stain EM (top) and 2D-class averages

681   (bottom) of purified CCT/TriC. Scalebar, 100 nm.

682

683   **Extended Data Figure 2. MultiMate assembly for baculovirus-vectored delivery of large**

684   **multifunctional DNA in human cells. a**, MultiMate-Rainbow assembly in a schematic view.

685   Individual modules in pMMACE, pMMDS DEST and pMMK ENTR as shown (upper panel).

686   Two LR reactions resulted in MultiMate-5-colours and pMMDS-2-colours (middle panel),

687   fused by Cre-mediated recombination *in vitro* to produce MultiMate-Rainbow. **b**, Restriction

688   mapping of five clones each of MultiMate-5-colours (left) pMMDS-2-colours (middle) and

689   Cre-recombined MultiMate-Rainbow (right) evidences robust assembly. **c**, Confocal images

690   of HEK293T, HeLa, H4 and SH-SY5Y cells 48 hours after transduction with MultiMate-5-

691   colours VSV-G pseudotyped BV[19]. Scalebar, 20 μm. **d**, Schematic representation of

692   MultiMate-CellCycle assembly. Individual modules were pasted in pMMACE and pMMK

693   ENTR plasmids (upper panel). **e**, Restriction mapping of five clones each after LR

694   recombination. **f**, Confocal microscopy of HEK293T, SH-SY5Y, HeLa and H4 cells at 48

695   hours after transduction with MutiMate-CellCycle VSV-G pseudotyped BV. Scalebar, 100 μm.

696

697   **Extended Data Figure 3. Baculovirus-vectored delivery of complete multicomponent**

698   **CRISPR/Cas9 toolkits for homology independent targeted integration (HITI) in human**

699   **cells, continued**. **a-c,** HEK293T cells transfected with MultiMate-HDR or HITI-2c all-in-one

700   plasmids in the absence of puromycin selection at three- or 14-days post transfection. **a**,

701   representative flow-cytometry plots; **b**, Histograms of absolute (left) and relative (right) gene

702   editing efficiencies. Flow-cytometry data of n = 3 independent biological replicates.

703   ***P<0.001, Student's t-test. Relative gene editing efficiency is calculated as the % of

704   mCherry+ cells over the % of eGFP+ cells. **c**, Confocal microscopy of HEK293T at two-days

705   post transfection with MultiMate-HDR or MultiMate-HITI-2c plasmids. Scalebar, 50 μm. **d**,

706   Representative flow-cytometry histograms of HEK293T transfected with MultiMate-HDR or

707   MultiMate-HITI-2c after puromycin selection. **e**, Genotype PCR of HEK293T transfected

708   (upper panel) or transduced (lower panel) with MultiMate-HDR or MultiMate-HITI-2c after

709   puromycin selection. **f**, Widefield microscopy images of live HEK293T transfected with

710   MultiMate-HDR or MultiMate-HITI-2c plasmids after puromycin selection. Scalebar, 100 μm.

711   **g**, Western blot of total protein extracts from puromycin selected HEK293T transfected with

712   MultiMate-HDR, MultiMate-HITI-2c and untransfected HEK293T as a control (ctr). Anti-β-

713   actin antibody was used in top panel, with anti-TUBULIN as a loading control. **h**,

714   Representative confocal images of HEK293T, HeLa, H4 and SH-SY5Y human cells 72 hours

715   after transduction with MultiMate-HDR or HITI-2c BV. Scalebar, 50 μm. **i**, Representative

716   flow-cytometry plots of HEK293T, HeLa, H4 and SH-SY5Y cells at three-days post

717   transduction with MultiMate-HITI-2c BV, untransduced parental cell lines as a control (ctr).

718

719   **Extended Data Figure 4. Baculovirus-vectored safe-harbour homology-independent**

720   **integration of large DNA cargoes in human genomes, continued. a-b**, Delivery efficiencies

721   of indicated MultiMate-HITI-2c plasmids by transfection (**a**) or low-titer BV transduction (b)

722   in HEK293T at three-days post transfection/transduction. **c-d**, Absolute gene editing

723   efficiencies of HEK293T at three-days post transfection (c) or low-titer BV transduction (d)

724   with the indicated MultiMate-HITI-2c plasmids. Mean ± s.d. of n = 3 independent biological

725   replicates. Dots and triangles represent total MultiMate plasmid and HITI-2c payload DNA

726   sizes, respectively. **e-f**, Representative flow-cytometry histograms of HEK293T transduced

727   with the indicated MultiMate-HITI-2c BVs and selected with puromycin or

728   puromycin/hygromycin for mCherry expression (**e**) or eGFP/EYFP expression (f).

729

730   **Extended Data Figure 5. Highly efficient and indels-free prime-editing by using**

731   **MultiMate all-in-one BV**, **continued a**, Restriction mapping of five randomly picked

732   MultiMate-PE2 clones. **b**, Confocal microscopy images of HEK293T two-days after

733   transfection with MultiMate-PE2 plasmid. **c**, Representative genotype PCR Sanger sequencing

734   of HEK293T four-days after transfection with MultiMate-PE2 and relative sequences

735   contribution after Sanger sequencing deconvolution (ICE). Mean ± s.d. of n = 3 independent

736   biological replicates. **d**, Visual summary of BV amplification. V0: widefield images of Sf21

737   cells in 6-well plates after initial transfection with MultiMate-PE2 BV DNA and control cells

738   (untransfected). All transfected cells show VSV-G induced syncytia. V2: aeBlue expression in

739   suspension culture (upper panel) and centrifuged pellets (lower panel) of Sf21 cells during

740   amplification of MultiMate-PE2 BVs. **e**, Confocal microscopy images of HeLa, RPE-1

741 hTERT, HEK293T and SH-SY5Y at 24-hours post transduction with MultiMate-PE2 BV. **f**,

742 Representative flow-cytometry histograms of mTagBFP expression in HEK293T at 24-hours

743 post transduction. Dotted lines represent gating. **g**, Transduction efficiencies of HEK293T at

744 24-hours post-transduction with the indicated dilutions of MultiMate-PE2 BV. Mean ± s.d. of

745 n = 5 independent biological replicates. **h**, Sanger sequencing comparisons of of *HEK3* locus

746 in HEK293T six days after transduction with the indicated amounts of MultiMate-PE2 BV. **i**,

747 Percentage of correct editing (CTT insertion) in HEK293T six days post transduction with the

748 indicated amounts of MultiMate-PE2 BV. Data are derived from Sanger sequencing

749 deconvolution (ICE), no indels were detected in any of the conditions. Mean ± s.d. of n = 3

750 independent biological replicates.

Fig1_AulicinoBerger

ExtDataFig1_AulicinoBerger

a

DEST   pMMACE_DEST CMV H2B
ENTR 1 pMMK ENTR 1 CMV EYFP Tubulin
ENTR 2 pMMK ENTR 2 CMV mTFP1 Actin
ENTR 3 pMMK ENTR 3 CMV mito mCherry
ENTR 4 pMMK ENTR 4 CMV CyOFP1 ER

DEST   pMMDS_Empty vector
ENTR 1 pMMK ENTR 1 CMV mAG β-catenin
ENTR 2 pMMK ENTR 2 Empty vector
ENTR 3 pMMK ENTR 3 Empty vector
ENTR 4 pMMK ENTR 4 CMV GTS mTagBFP

MultiMate-5-colours (18 kb)

pMMDS 2 colours (8 kb)

MultiMate-Rainbow (23.4 kb)

b

MultiMate-5-colours (18 kb)   EcoRV

pMMDS 2 colours (8 kb)   EcoRI/HindIII

MultiMate-Rainbow (23.4 kb)   EcoRI

c

MultiMate-5-colours BV transduction

H2B iRFP | EYFP Tubulin | mTFP1 Actin | mito mCherry | CyOFP1 ER

HEK293T | HeLa | H4 | SH-SY5Y

d

DEST   pMMACE DEST CMV H2B-iRFP
ENTR 1 pMMK ENTR1 CMV mAG-hGeminin
ENTR 2 pMMK ENTR2 CMV mKO2-hCdt1
ENTR 3 pMMK ENTR 3 empty vector
ENTR 4 pMMK ENTR 4 empty vector

MultiMate-CellCycle (9.1 kb)

e

MultiMate-CellCycle (9.1 kb)   EcoRV

f

MultiMate-CellCycle BV transduction

H2B iREP720 | mAG hGeminin | mKO2 hCdt1 | Merge

HEK293T | SH-SY5Y | HeLa | H4

ExtDataFig2_AulicinoBerger

Fig2_AulicinoBerger

ExtDataFig3_AulicinoBerger

Fig3_AulicinoBerger

ExtDataFig4_AulicinoBerger

Fig4_AulicinoBerger